-

Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell™ for Treatment of COPD

Therapeutic Solutions International Continues Parallel Development of COPD Program in Conjunction with Pivotal Clinical Trial in COVID-19

OCEANSIDE, Calif.--(BUSINESS WIRE)--Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCell™ through induction of a specific cell type called “Myeloid Derived Progenitor Cells”.

In a series of experiments, mice were treated with JadiCells, Myeloid Derived Suppressor Cells, and a combination of the two. It was found that the combination possessed superior ability to reduce lung damage and stimulate pulmonary regeneration. Additionally, administration of the FDA cleared drug Leukine was demonstrated to naturally increase levels of Myeloid Derived Suppressor cells and enhance activity of the JadiCells.

“As a medical doctor that routinely sees the devastation caused by COPD, I am extremely excited about the possibility of curing this disease” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “But in order to even begin talking about cures, we need to realize that a pathology as complex as COPD will not be cured by a 'magic bullet.' Therefore, we are always searching for new ways to continually increase the efficacy of our approaches.”

The Company recently filed an Investigational New Drug application for using its Phase III stem cells, called JadiCells, for treatment of COPD1.

“These recent data are a result of our multidisciplinary approach to chronic diseases. Since there is an immunological mechanism at play here, we are currently in discussion with several immunotherapy stakeholders for collaborations and partnerships” said Timothy Dixon, President and CEO of the Company and co-inventor of the patent.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells

Contacts

Timothy G. Dixon
ir@tsoimail.com

Therapeutic Solutions International

OTC Pink:TSOI

Release Versions

Contacts

Timothy G. Dixon
ir@tsoimail.com

More News From Therapeutic Solutions International

Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases

ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office regarding its patent application entitled “Stimulation of Mesenchymal Stem Cell Therapeutics Activities by Regulatory T Cells.” The issued patent claims include: “A method of inhibiting lung inflammation comprising: a) identifying a subject suffering from lung inflammation; b) administering a population of T regula...

Immunology Based Suicide Prevention Company Campbell Neurosciences Announces Appointment of Public Company Veteran Raymond Oliver as Chairman of the Board

ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. (TSOI) Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company. Therapeutic Solutions International pre-spin-off company, Campbell Neurosciences, Inc., announced today appointment of seasoned public company veteran Mr. Raymond Oliver as Chairman of its Board of Directors. This move is part of a larger strategy the suicide prevention company is impl...

Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers1. The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® relat...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.